aTyr PharmaATYR
About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Employees: 59
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
329% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 7
136% more capital invested
Capital invested by funds: $84.3M [Q3] → $199M (+$114M) [Q4]
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
40% more funds holding
Funds holding: 55 [Q3] → 77 (+22) [Q4]
2.21% more ownership
Funds ownership: 63.17% [Q3] → 65.38% (+2.21%) [Q4]
18% less call options, than puts
Call options by funds: $195K | Put options by funds: $237K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 85 / 422 met price target | 1,115%upside $35 | Buy Reiterated | 14 Mar 2025 |
Leerink Partners Faisal Khurshid 17% 1-year accuracy 2 / 12 met price target | 456%upside $16 | Outperform Initiated | 18 Feb 2025 |
Financial journalist opinion
Based on 9 articles about ATYR published over the past 30 days









